Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - TG THERAPEUTICS, INC. | v102717_ex992.htm |
| EX-99.1 - EXHIBIT 99.1 - TG THERAPEUTICS, INC. | v102617_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
_____________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of report
(Date of earliest event reported): October 26, 2017
TG Therapeutics, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware
(State or Other
Jurisdiction
of
Incorporation)
|
001-32639
(Commission File
Number)
|
36-3898269
(IRS Employer
Identification No.)
|
2 Gansevoort Street, 9th
Floor
New York, New York 10014
(Address of
Principal Executive Offices)
(212) 554-4484
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
|
Written communications pursuant to Rule 425
under the Securities Act.
|
|
☐
|
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act.
|
|
☐
|
|
Pre-commencement communications pursuant to Rule
14d-2b under the Exchange Act.
|
|
☐
|
|
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act.
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2). Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On
October 26, 2017, TG Therapeutics, Inc. (the “Company”)
issued a press release announcing results from the Phase 2
multicenter trial of TG-1101 (ublituximab) in relapsing forms of
Multiple Sclerosis (RMS) presented during the 7th Joint ECTRIMS
– ACTRIMS meeting in Paris, France. On October 27, 2017, the
Company announced additional results from the Phase 2 multicenter
trial of TG-1101 in RMS presented during the 7th Joint ECTRIMS
– ACTRIMS meeting. Copies of the press releases are being
filed as Exhibits 99.1 and 99.2 and incorporated in this Item by
reference.
Item 9.01 Financial Statements And
Exhibits.
(d)
Exhibits.
99.1 Press Release, dated October 26,
2017.
99.2 Press Release, dated
October
27,
2017.
-2-
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
Date:
October
27, 2017
|
|
|
|
By: /s/
Sean A.
Power
|
|
|
Sean A.
Power
|
|
|
Chief Financial
Officer
|
|
|
|
-3-